Amy Holleman, Meyling H. Cheok, Monique L. den Boer, Wenjian Yang, Anjo J.P. Veerman, Karin M. Kazemier, Deqing Pei, Cheng Cheng, Ching-Hon Pui, Mary V. Relling, Gritta E. Janka-Schaub, Rob Pieters, and William E. Evans
Supplemental Figure 1:
Unsupervised hierarchical clustering discriminating drug resistant and drug sensitive ALL patients.
Supplemental Figure 2:
Data analysis flowchart.
Supplemental Figure 3:
Supervised hierarchical clustering discriminating drug resistant and drug sensitive ALL patients (B- and T-lineage ALL).
Supplemental Figure 4:
Principal component analysis of drug resistant and sensitive ALL samples for the four antileukemic agents (B- and T-lineage ALL).
Supplemental Figure 5:
Supervised hierarchical clustering discriminating prednisolone resistant and sensitive B-lineage ALL.
Supplemental Figure 6:
Supervised hierarchical clustering discriminating vincristine resistant and sensitive B-lineage ALL.
Supplemental Figure 7:
Supervised hierarchical clustering discriminating L-asparaginase resistant and sensitive B-lineage ALL.
Supplemental Figure 8:
Supervised hierarchical clustering discriminating daunorubicin resistant and sensitive B-lineage ALL.
Supplemental Figure 9:
Supervised hierarchical clustering discriminating prednisolone resistant and sensitive ALL (B- and T-lineage ALL).
Supplemental Figure 10:
Supervised hierarchical clustering discriminating vincristine resistant and sensitive ALL (B- and T-lineage ALL).
Supplemental Figure 11:
Supervised hierarchical clustering discriminating L-asparaginase resistant and sensitive ALL (B- and T-lineage ALL).
Supplemental Figure 12:
Supervised hierarchical clustering discriminating daunorubicin resistant and sensitive ALL (B- and T-lineage ALL).
Supplemental Figure 13:
Gene Ontology classification of genes discriminating drug resistance in patients with acute lymphoblastic leukemia (B- and T-lineage ALL).
Supplemental Figure 14:
Pathway analysis of genes associated with L-asparaginase resistance in B-lineage ALL.
Supplemental Table 1:
LC50 values for classification of resistant and sensitive ALL for each chemotherapeutic agent.
Supplemental Table 2:
Patient characteristics.
Supplemental Table 3:
Permutation analysis and false discovery rate of probe sets selected by Wilcoxon rank sum test and t-test.
Supplemental Table 4:
Number of significant probe sets discriminating drug resistance for each individual antileukemic agent.
Supplemental Table 5:
Prediction accuracy using gene expression profiles for classification of drug resistant and sensitive acute lymphoblastic leukemia. 9
Supplemental Table 6:
Gene expression scores for the intermediate sensitivity group, using genes selected to discriminate resistant and sensitive B-lineage ALL.
Supplemental Table 7:
Genes previously linked to drug resistance or prognosis in ALL.
Supplemental Table 8:
Multivariate analysis of gene expression and known prognostic factors (age, WBC count) to discriminate in vitro drug resistance.
Supplemental Table 9:
Association of the LC50 scores with gene expression scores and other known prognostic variables.
Supplemental Table 10:
Association of the drug resistance gene expression scores and minimal residual disease (MRD).